New Alzheimer’s drugs have brought hope to many, but like any medication, they come with risks. These drugs, such as Leqembi and Kisunla, are part of a class known as anti-amyloid drugs. They work by targeting and removing amyloid plaques from the brain, which are believed to contribute to Alzheimer’s disease. However, one of the significant risks associated with these drugs is a condition called amyloid-related imaging abnormalities (ARIA), which can cause brain swelling and small bleeds.
The risk of ARIA is particularly higher in people who carry two copies of the ApoE4 gene. This genetic factor increases the likelihood of experiencing side effects from these medications. During the early clinical trials for these drugs, participants were not informed about their genetic risk, partly because the link between the ApoE4 gene and side effects was not as clear at the time. Now that this connection is better understood, there is a growing discussion about whether drug companies should disclose genetic risks to patients.
Another concern with these drugs is their potential impact on people without specific genetic risks. While they may offer benefits for some, the long-term effects and potential side effects for a broader population are still being studied.
In addition to these anti-amyloid drugs, other types of medications, such as those used for diabetes, are being explored for their potential to reduce Alzheimer’s risk. GLP-1 and SGLT2 drugs, commonly used to treat diabetes, have shown promise in possibly lowering the risk of dementia. However, more research is needed to confirm their effectiveness in people without diabetes.
Overall, while new Alzheimer’s drugs offer hope, it’s crucial for patients and their families to be aware of the potential risks and to discuss these with healthcare providers. Regular monitoring and careful consideration of genetic factors are essential for safe and effective treatment.
